clinical trial · NCT06345404
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Atopic DermatitisSoquelitinibPlacebo
brief summary
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
started
Apr 16, 2024
primary completion
Jan 28, 2026
completion
Feb 24, 2026
last updated
Mar 12, 2026
detailed description
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants with Moderate to Severe Atopic Dermatitis
official title
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol